Neurogene Management
Management criteria checks 1/4
Neurogene's CEO is Rachel McMinn, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $1.08M, comprised of 43.3% salary and 56.7% bonuses, including company stock and options. directly owns 8.75% of the company’s shares, worth €32.98M. The average tenure of the management team and the board of directors is 0.9 years and 0.9 years respectively.
Key information
Rachel McMinn
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 43.3% |
| CEO tenure | 6.8yrs |
| CEO ownership | 8.8% |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$3m |
| Jun 30 2024 | n/a | n/a | US$2m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$1m | US$468k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$51m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$657k | US$448k | -US$55m |
Compensation vs Market: Rachel's total compensation ($USD1.08M) is about average for companies of similar size in the German market ($USD995.28K).
Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.
CEO
Rachel McMinn (51 yo)
6.8yrs
Tenure
US$1,080,629
Compensation
Dr. Rachel L. McMinn, Ph D., is the Founder of Neurogene Inc. and Chief Executive Officer and Executive Chair of Board since December 2023. Dr. McMinn founded Private Neurogene in January 2018 and served a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.8yrs | US$1.08m | 8.75% € 33.0m | |
| President | less than a year | US$1.13m | 0.52% € 2.0m | |
| Chief Scientific Officer | less than a year | US$784.32k | 0.14% € 518.1k | |
| Senior Vice President of Business Operations | no data | no data | no data | |
| Senior VP & General Counsel | less than a year | no data | 0% € 0 | |
| Senior Vice President of Early Clinical & Translational Research | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | no data | no data | no data | |
| Senior Vice President of Technical Operations | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
0.9yrs
Average Tenure
51yo
Average Age
Experienced Management: UU8's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | less than a year | US$1.08m | 8.75% € 33.0m | |
| Independent Director | less than a year | US$64.08k | 0% € 0 | |
| Independent Director | 2.7yrs | US$71.62k | 0% € 0 | |
| Independent Director | 5.3yrs | US$62.12k | 0% € 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | 0% € 0 |
0.9yrs
Average Tenure
56yo
Average Age
Experienced Board: UU8's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.